Risk–Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults

Purpose: To estimate the risk–benefit trade-off of a pediatric-inspired regimen versus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for first-line treatment of adolescents/young adult (AYA; ages 16–39 years) patients with Philadelphia-negative acute ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzauskas, Gregory F., Villa, Kathleen F., Vanhove, Geertrui F., Fisher, Vicki L., Veenstra, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346961/
https://www.ncbi.nlm.nih.gov/pubmed/27779442
http://dx.doi.org/10.1089/jayao.2016.0049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346961/
https://www.ncbi.nlm.nih.gov/pubmed/27779442
http://dx.doi.org/10.1089/jayao.2016.0049

Ejemplares similares